Long

Wall Street is Short VBIV, but I'm Long *Target: [$3.50]*

Updated
Link to Culper Research report that states they are shorting VBIV because the company is "worthless"
img1.wsimg.com/blobby/go/cc91fda7-4669-4d1b-81ce-a0b8d77f25ab/downloads/Culper_VBIV_6-2-2020.pdf?ver=1591103388750

First, it's always important to consider ALL information. It's also important to be transparent about knowledge. If you are going to make any VBIV trades you really should read the entire report.

1) I think many of the points made in the Culper Report are legitimate
2) I am not as optimistic about long term price targets as those seen at Guggenheim and on yahoo finance
3) I still believe this is a good short-term trade based on sentiment and momentum regarding June 22-24 release of clinical glioblastoma data

Stop loss @ $2.04
Trade closed: target reached
Closed trade at $2.41 today
biotechbiotechnologyChart PatternsTechnical IndicatorsLONGNVAXpumpTrend AnalysisVBIV

Also on:

Related publications

Disclaimer